Latest Andrew Witty Stories

Biota Holdings Limited (ASX: BTA) today announced it had concluded its litigation against GlaxoSmithKline (GSK). The announcement followed formal mediation between by the parties ordered by the Victorian Supreme Court. The mediation provided the parties with the opportunity to resolve their differences and eliminate the uncertainty and costs associated with the legal process. Biota and GSK have agreed to normalise their relationship to pursue the best interests of Relenza, with senior...

By Ben Hirschler, European Pharmaceuticals CorrespondentLONDON -- GlaxoSmithKline Plc continued its roll-out of new products on Wednesday, winning fresh regulatory approvals for two niche treatments to fight diabetes and cancer.Europe's biggest drug maker said it was launching Avandaryl, a two-in-one diabetes pill, in the United States and had been given a green light in Europe to market Hycamtin -- already used to fight ovarian tumors -- as a treatment for lung cancer.Both approvals had been...